Palonan (Palonosetron)

Palonosetron, the active ingredient in Palonan, is a 5‑HT3 receptor antagonist presented as an intravenous solution for injection use. It is employed to prevent nausea and vomiting associated with chemotherapy and surgery in adult patients. GNH USA supplies Palonan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Palonan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Palonosetron is used in the management of nausea and vomiting through its action on serotonin pathways.

- Chemotherapy‑induced nausea and vomiting (CINV): helps prevent the acute and delayed phases of CINV. - Post‑operative nausea and vomiting (PONV): reduces the incidence of nausea and vomiting after surgery. - Radiotherapy‑induced nausea and vomiting: assists in controlling the nausea associated with radiation treatment. - Antiemetic prophylaxis for high‑risk patients: provides additional protection for patients identified as high‑risk for severe emesis. - Adjunctive therapy in combination with other antiemetics: used alongside other agents to enhance overall anti‑emetic control. - Support for patients receiving highly emetogenic chemotherapy regimens.

Palonosetron is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects: - Headache  - Constipation  - Fatigue  - Dizziness  - Injection site discomfort  - Diarrhea 

Serious or Rare Side Effects: - Severe hypersensitivity reactions (anaphylaxis, angio‑edema)  - QT‑interval prolongation  - Cardiac arrhythmias  - Serotonin syndrome (when combined with serotonergic agents)  - Severe constipation or intestinal obstruction  - Neuro‑muscular weakness or respiratory depression.

Palonan should be used with consideration of patient‑specific factors and monitoring requirements.

- Pregnancy: safety data are limited; use only if the potential benefit justifies the potential risk. - Breastfeeding: it is unknown whether the drug passes into human milk; caution is advised. - Cardiac risk: monitor patients with known QT‑prolongation or electrolyte disturbances. - Concomitant serotonergic drugs: assess for additive serotonergic effects. - Renal or hepatic impairment: dose adjustment may be needed based on clinical judgment. - Store at 2-8°C: keep refrigerated ; protect from light ; do not freeze or shake.

Palonosetron may interact with several drug classes that affect cardiac rhythm or serotonin pathways.

Major Interactions (Avoid): - Drugs that prolong the QT interval such as certain antiarrhythmics, macrolide antibiotics ;  - Strong serotonergic agents (e.g., SSRIs, MAO‑inhibitors) that could increase serotonin syndrome risk.

Moderate Interaction (Monitor Closely): - CYP enzyme inducers or the C c t t c C c t C c c C t C c c C C C C C C C C C C C C C C C C -   t  t